# Alamar Biosciences, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Alamar Biosciences, Inc.). ## Overview Alamar Biosciences, Inc. develops and commercializes proteomics and immunoassay instruments, consumables, and related services for life-science research. Its core platform includes the ARGO HT instrument, NULISA assay consumables, and TAP services, with sales primarily in North America, Europe, and Asia through direct and distribution channels. ## Products & services • ARGO HT research instrument • NULISA assay consumables and kits • TAP Services for sample testing and analysis • Instrument maintenance and repair contracts • ARGO HT/DX diagnostic platform in development - **Instruments** (45%) — Benchtop analytical instruments used for proteomics and immunoassay workflows. - **Consumables** (40%) — Assay consumables and kits used on installed instruments for recurring testing. - **Services** (15%) — TAP Services, analytical testing, and maintenance/repair contracts. - ARGO HT research instrument - NULISA assay consumables and kits - TAP Services for sample testing and analysis - Instrument maintenance and repair contracts - ARGO HT/DX diagnostic platform in development ## Customers Customers are primarily academic and research institutions, biopharmaceutical companies, contract research organizations, and service laboratories. These buyers use Alamar’s platform for biomarker discovery, assay development, and research workflows that require sensitive multiplexed protein analysis. - **Academic and research institutions** (primary) — Universities and research centers buy instruments, consumables, and TAP Services for basic and translational research. - **Biopharmaceutical companies** (primary) — Drug developers use the platform for biomarker discovery, assay validation, and preclinical research. - **Contract research organizations** (secondary) — CROs purchase services and systems to support outsourced analytical programs for pharma and biotech clients. - **Service laboratories** (secondary) — Labs buy instruments and consumables to offer testing and analytical services to third parties. - **Distributors** (secondary) — Channel partners resell products in selected international markets where direct coverage is limited. - Academic and research institutions buying for discovery and publication work - Biopharmaceutical companies using the platform for biomarker and translational research - CROs and service labs running outsourced analytical testing for clients - Distributors supporting sales in selected international markets - Research foundations funding collaborations around disease biomarker discovery ## Geography Alamar sells primarily through direct channels in North America, Europe, and China, with additional distribution coverage in Australia, parts of Eastern Europe, India, Japan, Singapore, and South Korea. In the reported quarter, the Americas contributed 62% of sales, EMEA 29%, and APAC 9%, reflecting a business that is still anchored in U.S. research demand but increasingly international. - **Americas** (62%) - **EMEA** (29%) — Combined Europe, Middle East & Africa region disclosed by the company. - **APAC** (9%) — Asia-Pacific region disclosed by the company; country list is illustrative. - North America is the main commercial base and largest revenue region - Europe is a major market served through direct sales and distributors - China is a named direct-sales market and an important growth geography - APAC sales include Australia, Japan, Singapore, and South Korea - International expansion increases currency and supply-chain exposure ## Strategy The company is expanding its installed base by broadening sales coverage, adding new instruments, and improving the applications around its proteomics platform. It is also investing in future products, including ARGO HT/DX, to extend the platform from research use toward translational and diagnostic markets if regulatory approvals are obtained. - **Expand the installed base** (short-term) — A larger installed base increases recurring consumables demand and service revenue. - **Broaden product capabilities** (medium-term) — More applications and improved performance support adoption and customer retention. - **Enter translational and diagnostic markets** (long-term) — Future regulated products could expand the addressable market beyond RUO research use. - Expand global direct sales and distributor coverage - Grow the installed base to drive recurring consumables pull-through - Enhance ARGO HT capabilities and software applications - Develop new instruments for discovery, translational, and diagnostic use - Use TAP Services to support proof-of-concept and customer adoption ## Risks The business depends on a small number of specialized suppliers and on customer funding cycles, so supply interruptions or grant-driven demand swings can materially affect sales timing. It also faces regulatory and execution risk as it develops products intended for diagnostic use, while international operations add foreign exchange and trade-related exposure. - **Single-source supply dependence** [high] — A majority of key antibodies and some instrument components come from single suppliers, creating shortage risk. - **Customer funding and seasonality** [medium] — Many customers rely on government grants and year-end budgets, which can shift purchase timing. - **Regulatory transition risk** [high] — If products are viewed as clinical diagnostics, marketing authorization could be required before sale. - **Foreign exchange volatility** [medium] — A portion of revenue is denominated in euros and other foreign currencies, affecting reported results. - **Trade and logistics disruption** [medium] — Tariffs, shipping delays, and labor shortages can disrupt supply and customer delivery. - Single-source suppliers for key antibodies and components - Customer demand depends on research budgets and grant cycles - Long and variable sales cycles for instrument adoption - Regulatory risk if RUO products move toward clinical use - Foreign exchange and trade restrictions affect international sales ## Accounting Revenue is recognized at different points depending on the offering: instruments on delivery, consumables on shipment, TAP Services when results are delivered, and maintenance contracts over time. Investors should also watch inventory reserves, warranty costs, foreign currency effects, and the fair-value accounting for convertible notes, all of which can move reported results and comparability across quarters. - **Revenue recognition by product type** — Can create quarter-to-quarter volatility in reported sales - **Seasonality** — Makes first-quarter and fourth-quarter results less comparable - **Inventory reserves and warranty obligations** — Affects gross margin and cost of revenue - **Convertible note fair value** — Can add volatility below operating income - **Foreign currency exposure** — Can affect revenue, expenses, and other income/expense - Point-in-time revenue for instruments and consumables - Over-time revenue for maintenance contracts - Service revenue recognized when analytical results are delivered - Inventory obsolescence and warranty reserves affect cost of revenue - Convertible notes measured at fair value create remeasurement gains/losses - Foreign currency translation affects international revenue and expenses --- *Last updated: 2026-08-11T04:46:19.829332+00:00*